VolitionRx Ltd. has announced the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference, where results from a recent clinical study will be presented. The session, led by Professor Evangelos J. Giamarellos-Bourboulis, will focus on the use of the Nu.Q® NETs assay as a blood test for classifying Hidradenitis Suppurativa (HS) patients and guiding treatment selection and modification. The study demonstrates that Nu.Q® NETs can be used to support personalized treatment approaches for HS, a chronic disease affecting approximately 1% of the global population. The Nu.Q® NETs assay is CE-Marked and available for clinical use in the European Union, European Economic Area countries, and the United Kingdom. Data from the study will be presented at the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN78480) on February 04, 2026, and is solely responsible for the information contained therein.